Passage Bio Revenue and Competitors

Location

$379.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Passage Bio's estimated annual revenue is currently $25.9M per year.(i)
  • Passage Bio's estimated revenue per employee is $281,359
  • Passage Bio's total funding is $379.5M.
  • Passage Bio's current valuation is $311.1M. (January 2022)

Employee Data

  • Passage Bio has 92 Employees.(i)
  • Passage Bio grew their employee count by -30% last year.

Passage Bio's People

NameTitleEmail/Phone
1
VP Manufacturing OperationsReveal Email/Phone
2
VP, Clinical DevelopmentReveal Email/Phone
3
VP Clinical OperationsReveal Email/Phone
4
VP, BiologyReveal Email/Phone
5
SVP Corporate Development & Investor RelationsReveal Email/Phone
6
SVP Regulatory AffairsReveal Email/Phone
7
VP Supply Chain and CMC PlanningReveal Email/Phone
8
Senior Director, ControllerReveal Email/Phone
9
Executive Director Analytical Development & Quality ControlReveal Email/Phone
10
Director Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Passage Bio?

Passage Bio was launched with the vision to be a first in class fully-integrated genetic medicines company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 6 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn?s Orphan Disease Center to support these efforts.

keywords:N/A

$379.5M

Total Funding

92

Number of Employees

$25.9M

Revenue (est)

-30%

Employee Growth %

$311.1M

Valuation

N/A

Accelerator

Passage Bio News

2022-04-17 - Passage Bio Announces Inducement Awards Under Nasdaq ...

PHILADELPHIA, April 22, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on...

2022-04-06 - Passage Bio: Worth Keeping An Eye On

Genetic engineering concept. DNA. Gene therapy. Medical technology. metamorworks/iStock via Getty Images. I first became aware of Passage Bio...

2022-03-30 - Passage Bio helping to revitalize old Bristol Myers-Squibb site

Passage Bio has licensed nine options, out of an initial 17 potential ones, for gene therapies which are connected to research out of UPenn's...

2021-10-06 - Passage Bio : Announces Pennsylvania Scholars Program to Honor Legacy of Biopharma Pioneer Dr. Tachi Yamada

October 6, 2021 Download(opens in new window) Philadelphia, PA - October 6, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced a scholarship program dedicated t ...

2019-09-04 - Passage Bio Closes $110 Million Series B Financing

PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced the closing of a $110.0 million Series B financing. The financing round was ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.3M92-13%N/A
#2
$18.9M920%N/A
#3
$24.8M9210%N/A
#4
N/A9253%N/A
#5
$15.3M939%N/A